Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07672925

FlowMD Feasibility Study

The goal of this clinical trial is to learn if the FlowMD mobile app is feasible to be used to manage mild anxiety in adults. It will also learn if the app is effective at managing anxiety in adults.

Participants will:

Use the FlowMD app daily to complete a 1-5 minute guided breathwork session over the course of 4 weeks.

Complete surveys at the beginning, midpoint, and end of the study to measure anxiety levels and usability of the app.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Anxiety Anxiety Disorders Mental Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Helfgott Research Institute

Portland, Oregon, 97201, United States

Location status: Recruiting

Location contact

Michelle T Berg, Master of Clinical Research

CONTACT

[email protected]

1 503 552 1885

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are 18-65 years old
  • Have an anxiety disorder
  • Have a smartphone
  • Able to download the FlowMD app
  • Willing to use the FlowMD meditation app for a daily 1-5 minute session for four consecutive weeks
  • Able to provide feedback on the experience using the app
  • Willing to participate in surveys to measure changes in anxiety levels

Exclusion criteria

  • Are undergoing significant changes in psychiatric medication or therapy
  • Have severe psychiatric conditions that might interfere with study participation (Schizophrenia, Bipolar Disorder, Major Depressive Disorder)

Treatment and study plan

Intervention

Other

4 weeks daily usage of FlowMD guided breathwork sessions

Primary outcomes

  1. Feasibility of the FlowMD mobile app

    Time frame: From enrollment to end of intervention at 4 weeks

    Outcome measured using the Feasibility Survey with a Max Score of 32 indicating strong feasibility

Secondary outcomes

  1. Generalized Anxiety Disorder-7 (GAD-7) Score

    Time frame: From Enrollment to the end of the intervention at 4 weeks

    Outcome measured using the Generalized Anxiety Disorder-7 (GAD-7) survey. Score scale 0-21. Lower score indicates condition improvement.

  2. Hamilton Anxiety Rating Scale (HAM-A) Score

    Time frame: From Enrollment to the end of the intervention at 4 weeks

    Outcome measured using the Hamilton Anxiety Rating Scale (HAM-A) survey. Score scale 0-56. Lower score indicates condition improvement.

  3. State-Trait Anxiety Inventory (STAI)

    Time frame: From Enrollment to the end of the intervention at 4 weeks

    Outcome measured using the State-Trait Anxiety Inventory (STAI) survey. Score scale 20-80. Lower score indicates condition improvement.

Study contacts

Contact information is provided by the study sponsor or research team.

Michelle T Berg, Master of Clinical Research

CONTACT

[email protected]

1 503 552 1885

Sponsors and collaborators

Lead sponsor

National University of Natural Medicine

Other

Registry information

Official study title

Feasibility of Using a Meditation App in Adults With Anxiety Disorder

Acronym: FLowMD

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jun 29, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.